Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Neurosci
2005 May 18;2520:5051-60. doi: 10.1523/JNEUROSCI.0128-05.2005.
Show Gene links
Show Anatomy links
Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine.
Schenzer A, Friedrich T, Pusch M, Saftig P, Jentsch TJ, Grötzinger J, Schwake M.
???displayArticle.abstract???
Epilepsy is caused by an electrical hyperexcitability in the CNS. Because K+ channels are critical for establishing and stabilizing the resting potential of neurons, a loss of K+ channels could support neuronal hyperexcitability. Indeed, benign familial neonatal convulsions, an autosomal dominant epilepsy of infancy, is caused by mutations in KCNQ2 or KCNQ3 K+ channel genes. Because these channels contribute to the native muscarinic-sensitive K+ current (M current) that regulates excitability of numerous types of neurons, KCNQ (Kv7) channel activators would be effective in epilepsy treatment. A compound exhibiting anticonvulsant activity in animal seizure models is retigabine. It specifically acts on the neuronally expressed KCNQ2-KCNQ5 (Kv7.2-Kv7.5) channels, whereas KCNQ1 (Kv7.1) is not affected. Using the differential sensitivity of KCNQ3 and KCNQ1 to retigabine, we constructed chimeras to identify minimal segments required for sensitivity to the drug. We identified a single tryptophan residue within the S5 segment of KCNQ3 and also KCNQ2, KCNQ4, and KCNQ5 as crucial for the effect of retigabine. Furthermore, heteromeric KCNQ channels comprising KCNQ2 and KCNQ1 transmembrane domains (attributable to transfer of assembly properties from KCNQ3 to KCNQ1) are retigabine insensitive. Transfer of the tryptophan into the KCNQ1 scaffold resulted in retigabine-sensitive heteromers, suggesting that the tryptophan is necessary in all KCNQ subunits forming a functional tetramer to confer drug sensitivity.
Biervert,
A potassium channel mutation in neonatal human epilepsy.
1998, Pubmed,
Xenbase
Biervert,
A potassium channel mutation in neonatal human epilepsy.
1998,
Pubmed
,
Xenbase Brown,
Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone.
1980,
Pubmed Charlier,
A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family.
1998,
Pubmed Chen,
KCNQ1 gain-of-function mutation in familial atrial fibrillation.
2003,
Pubmed Cooper,
Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy.
2000,
Pubmed Doyle,
The structure of the potassium channel: molecular basis of K+ conduction and selectivity.
1998,
Pubmed Etxeberria,
Three mechanisms underlie KCNQ2/3 heteromeric potassium M-channel potentiation.
2004,
Pubmed
,
Xenbase Gutman,
International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels.
2003,
Pubmed Jentsch,
Neuronal KCNQ potassium channels: physiology and role in disease.
2000,
Pubmed Jiang,
Crystal structure and mechanism of a calcium-gated potassium channel.
2002,
Pubmed Jiang,
X-ray structure of a voltage-dependent K+ channel.
2003,
Pubmed Kubisch,
KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness.
1999,
Pubmed
,
Xenbase Main,
Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
2000,
Pubmed
,
Xenbase Neyroud,
A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome.
1997,
Pubmed Schroeder,
KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents.
2000,
Pubmed Schroeder,
Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy.
1998,
Pubmed
,
Xenbase Schwake,
A carboxy-terminal domain determines the subunit specificity of KCNQ K+ channel assembly.
2003,
Pubmed
,
Xenbase Schwake,
Surface expression and single channel properties of KCNQ2/KCNQ3, M-type K+ channels involved in epilepsy.
2000,
Pubmed
,
Xenbase Singh,
A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns.
1998,
Pubmed Swartz,
Towards a structural view of gating in potassium channels.
2004,
Pubmed Tatulian,
Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells.
2003,
Pubmed Tatulian,
Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
2001,
Pubmed Vriend,
WHAT IF: a molecular modeling and drug design program.
1990,
Pubmed Wang,
Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias.
1996,
Pubmed Wang,
KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel.
1998,
Pubmed
,
Xenbase Watanabe,
Glycosylation affects the protein stability and cell surface expression of Kv1.4 but Not Kv1.1 potassium channels. A pore region determinant dictates the effect of glycosylation on trafficking.
2004,
Pubmed Wickenden,
Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells.
2001,
Pubmed
,
Xenbase Wickenden,
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.
2000,
Pubmed Wuttke,
The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate.
2005,
Pubmed
,
Xenbase Yang,
Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy.
1998,
Pubmed
,
Xenbase Zerangue,
A new ER trafficking signal regulates the subunit stoichiometry of plasma membrane K(ATP) channels.
1999,
Pubmed
,
Xenbase
